Kritische 8-K Meldungen
WARNUNG: Kritische 8-K-Meldung(en)
HOCH Abgang Schlüsselpersonen (13.02.2026)
HOCH Abgang Schlüsselpersonen (13.02.2026)
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 13.02.2026 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | espectively. 1 Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain |
| 19.12.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers |
| 02.06.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; |
| 29.05.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; |
| 11.10.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | ied as being incorporated therein by reference. Item 5.02 Departure of Directors or Certain Officers; Election of Direct |
| 02.10.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Co |
| 25.09.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | to buy the securities described herein. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; |
| 23.09.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; |
| 27.02.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | herein by reference. The information set forth in Item 5.02 of this Report with respect to Robyn Rapaport and Lindsey Ro |
| 15.02.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | herein by reference. The information set forth in Item 5.02 of this Report with respect to Robyn Rapaport and Lindsey Ro |
Stammdaten
CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead development candidate is CER-1236, an autologous T cell therapy candidate for the treatment of hematologic malignancies and solid tumors. The company was incorporated in 2021 and is based in South San Francisco, California.
Unternehmen & Branche
| Name | CERO THERAPEUTICS HOLDINGS, INC. |
|---|---|
| Ticker | CERO |
| CIK | 0001870404 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2836 · Biological Products, (No Diagnostic Substances) |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 38.330 USD |
| Beta | 0,24 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | -19,920,262 | 3,641,134 | -5,446,462 | ||
| 2025-09-30 | 10-Q | -4,856,395 | -9.10 | 3,911,394 | -4,543,162 | |
| 2025-06-30 | 10-Q | -5,417,315 | -61.71 | 6,202,322 | -1,633,901 | |
| 2025-03-31 | 10-Q | -5,105,931 | -1.59 | 7,991,414 | -329,386 | |
| 2024-12-31 | 10-K | -7,732,212 | -18.15 | 6,206,929 | -1,894,563 | |
| 2024-09-30 | 10-Q | -4,227,967 | -170.22 | |||
| 2024-06-30 | 10-Q | -2,448,654 | -302.32 | 7,370,765 | -2,481,868 | |
| 2024-03-31 | 10-Q | -1,727,483 | -12.24 | 9,052,656 | -3,979,097 | |
| 2024-02-13 | 10-K | -572,211 | -97.90 | |||
| 2024-02-13 | 10-Q | -572,211 | -###.## | |||
| 2023-12-31 | 10-K | -7,289,577 | -###.## | 5,126,302 | -42,057,695 | |
| 2023-09-30 | 10-Q | -334,028 | 8,470,621 | -13,767,099 | ||
| 2023-06-30 | 10-Q | -2,092,507 | -0.23 | 14,110,263 | -13,291,394 | |
| 2023-03-31 | 10-Q | -2,438,330 | -0.27 | 14,430,169 | -11,578,660 | |
| 2022-12-31 | 10-K | -667,736 | 42,367,032 | -11,000,154 | ||
| 2022-09-30 | 10-Q | 84,505 | 180,451,041 | -9,057,197 | ||
| 2022-06-30 | 10-Q | -111,569 | 179,724,777 | -8,159,431 | ||
| 2022-03-31 | 10-Q | -377,997 | 179,776,795 | -8,047,862 | ||
| 2021-12-31 | 10-K | -315,547 | 180,078,207 | -7,669,865 | ||
| 2021-09-30 | 10-Q | 0 | 301,000 | 24,000 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
Keine Insider-Käufe/Verkäufe in den letzten 12 Monaten.
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.